Sandoz, Amgen: CMS Part B Pay Proposal Makes It Hard To Track Biosimilars

Representatives from both Sandoz and Amgen complained that CMS’ proposal to put biosimilars that reference the same brand biologic into single billing codes would make it difficult to track the products, saying the policy would eliminate one of the identifying mechanisms for biosimilars. A recent study by economists found that payment policies would affect the market uptake of biosimilars more than would other factors such as naming. However, some drug industry lobbyists told Inside Health Policy last week that...